A US-based former GlaxoSmithKline (LSE: GSK) scientist has pled guilty to a charge of leaking trade secrets, two years after authorities filed a complaint.
Yu Xue is accused of emailing proprietary information that was to have been used to establish a competing company in China, including details from her own patent application in the area of oncology.
According to the British drugmaker’s code of conduct, information may not be released externally without prior approval.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze